Chronic Graft Versus Host Disease (cGvHD)Symptoms, Doctors, Treatments, Advances & More
Learn About Chronic Graft Versus Host Disease (cGvHD)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Cleveland Clinic Main Campus
Betty Hamilton is a Transplant Surgeon in Cleveland, Ohio. Dr. Hamilton has been practicing medicine for over 26 years and is rated as an Elite provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). Her top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Febrile Neutropenia, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Bone Graft.
Moffitt Cancer Center, Magnolia Campus
Taiga Nishihori is an Internal Medicine provider in Tampa, Florida. Dr. Nishihori is rated as an Elite provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Multiple Myeloma, Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Graft. Dr. Nishihori is currently accepting new patients.
Emory Winship Cancer Institute
Amelia Langston is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Langston has been practicing medicine for over 42 years and is rated as an Elite provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). Her top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Aplastic Anemia, Bone Marrow Transplant, and Bone Marrow Aspiration.
Summary: This study will be conducted to compare Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
Summary: The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: * Belumosudil (an immunotherapy) * Fluticasone (an intranasal cortic...